Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia
Constantine S Tam, John F Seymour, Andrew W Roberts
Seminars in Oncology | W B SAUNDERS CO-ELSEVIER INC | Published : 2016
C.S. Tam receives honoraria and research funding from Roche and AbbVie; J.F. Seymour receives honoraria and research funding from Genentech and AbbVie; A.W. Roberts receives research funding from Genentech and AbbVie, and is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone payments related to venetoclax.